Nestle
-
Nestlé Sells Peanut Allergy Drug, Ending the Food Giant’s Foray Into Biotech
Peanut allergy therapy Palforzia, which Nestlé acquired in a multi-billion dollar deal, has been sold to allergy product company Stallergenes Greer. Palforzia was the first FDA-approved drug for peanut allergy, but its sales were hampered by the Covid-19 pandemic.
-
The Phase 3 Alzheimer’s company few have heard of
Accera will soon deliver Phase 3 data on Alzheimer’s disease, so why has nobody heard of them?
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Samsung, Nestlé teaming up for IoT innovation, but details are scant
The Samsung Strategy and Innovation Center will team up with the Nestlé Institute of Health Sciences to apply wearable sensors and nutritional insights to “provide people with entirely new awareness into health and wellness,” the two companies said.
-
Morning Read: Helius Medical, U.S. Army enter clinical trial for TBI device, India seeks damages from Nestle over Maggi Noodles recall
Helius Medical Technologies and the U.S. Army Medical Research and Materiel Command have announced a clinical trial for a traumatic brain injury device, and India is asking for $99.3M from Nestle after food scare involving Maggi noodles.
-
Devices & Diagnostics, Health IT, Pharma, Startups
Flagship Ventures teaming up with AstraZeneca, Nestlé and Bayer to speed up startup growth
Cambridge firm Flagship Ventures just announced a series of corporate partnerships to flesh out early stage […]